摘要
卒中后多种病理机制共同作用使神经细胞进入死亡程序,恶化神经功能,从而增加残疾率和相关死亡率,给国家和社会造成严重的经济医疗负担。目前临床上尚缺乏多靶点协同治疗策略的药物抑制卒中继发性损害。中风醒脑液为陈绍宏教授研发的中药复方制剂并获国家专利,由大黄、红参、三七、川芎组成,主要用于治疗急性卒中继发性损害,临床前研究证实其具有抗炎、抗氧化、神经保护等作用,并且在临床应用中疗效显著,但其确切治疗机制仍不完全清楚。因此,本文归纳总结了中风醒脑液各药主要化学成分抑制卒中继发性损害的药理作用,并从抗炎、抗氧化、抗兴奋性毒性、神经保护等多靶点协同治疗机制进行探讨,以期为扩大基础研究和临床研究提供理论参考。
At stroke onset, multiple pathological processes work together to induce the programmed death of nerve cells and neurological deterioration, thereby lead to increased disability and related mortality which caused a serious economic and medical burden to the state and society. Currently, the multi-target drugs shortage still exists, which synergistically suppress the secondary damage induced by stroke. Zhongfeng Xingnao Liquid(ZXL) is a traditional Chinese medicine compound developed by Professor Chen Shaohong and obtained a patent in China. It comprises four drugs: Red ginseng, Panax notoginseng, Rhizoma Ligustici Chuanxiong and Rhei Radix et Rhizoma. ZXL is mainly used to prevent secondary damage during the acute phase of the stroke. The pre-clinical studies confirmed its anti-inflammatory effect, anti-oxidation and neuroprotective effect and ZXL shows a good clinical efficacy, while the exact mechanism remains unclear. In this review, we summarized the pharmacological effects of major active compounds of ZXL on suppressing the post-stroke neurologic damage, and explored the multi-target therapy and synergistic action mechanism of anti-inflammatory, anti-oxidative, anti-excitotoxic, and neuroprotective effects, in order to provide a theoretical reference for the further pre-clinical fundamental and clinical studies in stroke.
作者
刘磊
张宏
陈绍宏
张晓云
Liu Lei;Zhang Hong;Chen Shaohong;Zhang Xiaoyun(Affiliated Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610075)
出处
《中药药理与临床》
CAS
CSCD
北大核心
2021年第2期227-232,F0003,共7页
Pharmacology and Clinics of Chinese Materia Medica
基金
四川省科学技术厅重点研发项目(编号:2019YFS0544,2019YFS0082)。
关键词
中风醒脑液
卒中
化学成分
药理作用
Zhongfeng Xingnao Liquid
stroke
active compounds
pharmacological effects
